<DOC>
	<DOCNO>NCT02101437</DOCNO>
	<brief_summary>For acute coronary syndrome patient undergoing cardiac catheterization stenting , give dual antiplatelet drug ( dual antiplatelet agent ) therapy , choice basis medical criterion ( clinical guideline ) routine aspirin + clopidogrel aspirin + ticagrelor , accord medical guideline currently disposal alternative proposal ( unless adverse drug tolerance bleeding administer ) ; idea experiment acute coronary syndrome conventional cardiac catheterization stenting , platelet miRNA expression ( miR-96 , miR-200b , miR-495 , miR-107 ) cardiac catheterization interventional treatment clopidogrel ticagrelor acceptance platelet reactivity ( PRU ) correlation value ( give clopidogrel ticagrelor determine clinician , patient follow-up experiment track observation ) , aim explore different platelet reactivity ( hyper-reactive hypo-reactive ) , difference miRNA performance .</brief_summary>
	<brief_title>The Relationship Platelet Micro-RNA Expression Platelet Reactivity Patients Under Clopidogrel Ticagrelor Treatment</brief_title>
	<detailed_description />
	<criteria>1 DAPT ( dual antiplatelet therapy ) stable angina patient elective stent implantation . 2 . DAPT 24 hour treatment PRU ( platelet activity unit ) value . ( Drug unresponsive patient define PRU &gt; 235 ) . 1.Not suitable treatment patient DAPT . ( Active peptic ulceration bleed ) 2 patient aspirin , clopidogrel , ticagrelor , cilostazol medication intolerance . 3 contraindication aspirin , clopidogrel , ticagrelor , cilostazol drug usage ( heart failure patient suitable use cilostazol ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>